Skip to main content

Day: March 23, 2020

Medexus Provides a Business Update and Outlines Response to COVID-19 Pandemic

TORONTO, CHICAGO and MONTREAL, March 23, 2020 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today provided an update to its shareholders reaffirming the strength of its business and outlining the measures it has taken in light of the COVID-19 healthcare crisis.Since December 31, 2019, the outbreak of the novel strain of coronavirus, specifically identified as “COVID-19”, has resulted in governments worldwide enacting emergency measures to combat the spread of the virus, including the implementation of travel bans, quarantine periods and social distancing. The World Health Organization has declared COVID-19 a pandemic and, as the crisis deepens in North America, Medexus is actively assessing and responding where possible to its potential impact on the Company’s business.“Our...

Continue reading

Kimberly Lathroum Joins Arcutis as Vice President of Marketing

WESTLAKE VILLAGE, Calif., March 23, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Kimberly Lathroum has joined the company as Vice President of Marketing. In this new role, Ms. Lathroum will be responsible for all of Arcutis’ marketing efforts as the Company prepares for the potential future commercialization of its product candidates.“Kimberly is an exceptional marketing and commercialization executive with over 18 years of experience in the biopharmaceutical industry, 10 of which have been specifically focused on the dermatology market,” said Frank Watanabe, Arcutis’ President and Chief Executive...

Continue reading

HC2 Holdings Provides Business Update in Response to COVID-19 Impact

NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) — HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE: HCHC), a diversified holding company, today provided an update on the operations of its holding company and operating subsidiaries in response to the impact of the COVID-19 outbreak, including steps being taken to ensure employee safety during the continuing COVID-19 outbreak.HC2’s holding company and its subsidiaries continue to operate, mostly uninterrupted, and the management teams have been implementing their business continuity plans to ensure that their businesses are able to operate and to protect the health and safety of their employees, clients and other business partners as the COVID-19 outbreak continues.“Across our holding company and operating subsidiaries we are taking steps to ensure that we are able to operate as best as...

Continue reading

Beazley Breach Briefing: Ransomware remains top cyber security threat for businesses

New York, March 23, 2020 (GLOBE NEWSWIRE) — Ransomware attacks skyrocketed in 2019, according to the latest Beazley Breach Briefing, an annual update on cyber trends produced by leading cyber insurer Beazley.Beazley’s in-house team of breach experts, Beazley Breach Response (BBR) Services, reported the number of ransomware attack notifications against clients increased by 131% compared to 2018. With the growth in frequency, the sums demanded by cybercriminals also increased exponentially, sometimes reaching seven or even eight figures.Cyber criminals’ methods of attack continue to evolve, too. The two most common forms of attack to deploy ransomware are phishing emails and breaching poorly secured remote desktop protocol (RDP). RDP enables employees to access their work computer desktops or company’s primary server from home with...

Continue reading

Covid-19 update and 2019 Final Dividend

  23 March 2020G4S plcCovid-19 Update and 2019 Final DividendG4S, the leading global security company provides the following update on Covid-19.As reported on 11 March 2020, when G4S announced its 2019 preliminary full year results, the financial impact of Covid-19 has not been material in the context of the Group’s year-to-date performance.The Board notes that, in the period since 11 March 2020, the spread of the virus to countries outside Asia has accelerated and the World Health Organisation has declared Covid-19 a global pandemic.  Countermeasures that are being introduced by national governments have escalated rapidly with potentially significant implications for the level of economic activity across a wide range of business sectors and geographic markets.G4S is working with employees, customers, suppliers, regulators and governments...

Continue reading

Transactions by persons discharging managerial responsibilities and/or persons closely associated

COMPANY ANNOUNCEMENT 14/2020 – 23 MARCH 2020Pursuant to article 19 of regulation (EU) no. 596/2014 of the European Parliament and of the Council on market abuse Royal Unibrew A/S has received notification of the below transactions related to shares in Royal Unibrew A/S made by persons discharging managerial responsibilities in Royal Unibrew A/S and/or persons closely related with them.Royal Unibrew A/S hereby makes public pursuant to article 19(3) of regulation (EU) no. 596/2014 of the European Parliament and of the Council on market abuse the information on the below transaction related to shares in Royal Unibrew A/S made by persons discharging managerial responsibilities in Royal Unibrew A/S and/or persons closely related with them.1Details of the person discharging managerial responsibilities/person closely associateda)NameMargit Risager...

Continue reading

NTR Holding A/S: Årsrapport 2019

Selskabsmeddelelse nr. 3 – 2020København, den 23. marts 2020Årsrapport 2019Bestyrelsen i NTR Holding A/S har i dag behandlet og godkendt Selskabets årsrapport for regnskabsåret 2019. Årsrapporten har følgende hovedpunkter:Årets omsætning udgør DKK 86,4 mio., og koncernens resultat af fortsættende aktiviteter før skat udgør DKK 8,2 mio., hvilket er højere end forventet ved regnskabsårets start. I 2018 udgjorde omsætningen DKK 81,6 mio., og resultat af fortsættende aktiviteter før skat udgjorde DKK 6,2 mio. Omsætning og resultat er på niveau med de senest udmeldte forventninger om en omsætning i niveauet DKK 85 mio. og et resultat af fortsættende aktiviteter før skat på noget over DKK 7 mio. Koncernens totalindkomst udgør DKK 6,9 mio. Egenkapitalen udgør DKK 130,3 mio., svarende til en indre værdi pr. aktie på DKK 52,7. Bestyrelsen foreslår,...

Continue reading

BrainsWay Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights

PATTERSON, N.J., March 23, 2020 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today reported financial results for the quarter and full-year ended December 31, 2019, and provided an operational update.“We are very pleased with our solid fourth quarter and full-year 2019 results. Our strong results are indicative of the continued growing demand for our deep transcranial magnetic stimulation (Deep TMS) system in major depressive disorder (MDD) and obsessive compulsive disorder (OCD). In addition, we have achieved key progress in advancing our clinical pipeline for future potential applications,” stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. “Like other organizations, BrainsWay...

Continue reading

CEO of Champignon Brands Shares Strategic Goals in Exclusive NetworkNewsWire Broadcast

NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) — via NetworkNewsAudio – Champignon Brands Inc. (CSE: SHRM) today announces the broadcast of its audio interview with NetworkNewsAudio (“NNA”), one of 40+ brands in the InvestorBrandNetwork (“IBN”).The interview can be heard at: http://nnw.fm/S39TuChampignon Brands CEO Gareth Birdsall joins NNW’s Stuart Smith in an interview that delves into the company’s strategic plan to expand its portfolio and become a preeminent player in the emerging psychedelic medicine arena. Headquartered in Vancouver, Champignon aims to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health care and pharmaceutical products.Champignon’s portfolio of mushroom-derived consumer packaged goods (CPGs) includes the Company’s flagship brand, Vitality Superteas, which...

Continue reading

ManTech Schedules First Quarter Fiscal Year 2020 Earnings Release and Conference Call for April 29, 2020

HERNDON, Va., March 23, 2020 (GLOBE NEWSWIRE) — ManTech International Corporation (Nasdaq: MANT) will issue its first quarter fiscal year 2020 earnings press release after close of market Wednesday, April 29, 2020. Management will discuss financial results in a conference call beginning at 5 p.m. EDT.Analysts may participate in the conference call by dialing (877) 638-9567 (domestic) or (253) 237-1032 (international) and entering pass code 1580468. The conference call will be webcast simultaneously to the public through a link on the Investor Relations section of the ManTech website (http://investor.mantech.com). A replay of the conference call will be available on the ManTech website approximately 2 hours after the conclusion of the call.About ManTech International CorporationManTech provides mission-focused technology solutions...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.